Adecatumumab
Adecatumumab Basic information
- Product Name:
- Adecatumumab
- Synonyms:
-
- Adecatumumab
- Research Grade Adecatumumab (DHD17402)
- MT 201
- Research Grade Adecatumumab
- Adecatumumab (anti-EpCAM)
- CAS:
- 503605-66-1
- MW:
- 0
- Mol File:
- Mol File
Adecatumumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Adecatumumab Usage And Synthesis
Uses
Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status[1][2].
in vivo
Adecatumumab (300 μg/mouse; i.v. bolus injection; 3 times per week) inhibits tumor growth in B16/EpCAM xenograft tumor model in mice, both of human adecatumumab and mu-adecatumumab[2].
Both human adecatumumab and mu-adecatumumab (300 μg/mouse; i.v. bolus injection; single dose) exhibit a bi-exponential curve progression of serum concentration with an early distribution phase between 0 and 10 h and a terminal elimination phase[2].
| Animal Model: | Female immunocompetent C57BL/6 mice (6-10 weeks old) with B16/EpCAM (i.v.)[2] |
| Dosage: | 250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab |
| Administration: | 250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab |
| Result: | Both of them exhibited anti-tumor activity against B16/EpCAM cells in mice. Although human adecatumumab inhibited the size of tumor colonies mice, the number of colonies was only slightly reduced after treatment without significant difference. In contrast, mu-adecatumumab induced a highly significant reduction in the number of lung tumor colonies by >85%, and the few remaining tumor colonies were of very small size. |
References
[1] Kurtz JE, et al. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010 Jun;10(6):951-8. DOI:10.1517/14712598.2010.482098
[2] Lutterbuese P, et al. Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunol Immunother. 2007 Apr;56(4):459-68. DOI:10.1007/s00262-006-0218-7
AdecatumumabSupplier
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 18081075745
- chemflowtech@sina.com
- Tel
- 15817493340
- 981810490@qq.com